决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Changes in the Metabolism of GD2-Specific Murine CAR-T Cells After Co-Culturing with Melanoma.
使用诱导性 CAR-T 细胞的免疫治疗,是在接近体内条件下抑制肿瘤的有效方法。
诱导型CAR-T细胞免疫疗法是在接近体内条件下抑制癌症的有效方法。CAR-T细胞在面对的不是单个癌细胞而是肿瘤细胞群时,其代谢特征仍是值得研究的问题。我们的研究展示了小鼠GD2特异性CAR-T细胞在接触B78-21黑色素瘤细胞及暴露于B-21黑色素瘤三维球体结构时的代谢组特征。
Immunotherapy with the use of induced CAR-T cells is an effective method of cancer suppression in close to in vivo conditions. The question of the nature of metabolism of CAR-T cells in the conditions of fighting not against single cancer cells, but against tumor cells, remains relevant. Our studies have shown the metabolomic profile of mouse GD2-specific CAR-T cells upon contact with B78-21 melanoma tumor cells and upon exposure to B-21 melanoma 3D spheroid structures.
MEMBER ACCOUNT
登录成功会直接打开下一页。